MAX
Company Analysis Frequency Therapeutics, Inc.
1. Summary
Advantages
- Price (14.98 $) is less than fair price (15.29 $)
- The company's current efficiency (ROE=124.7%) is higher than the sector average (ROE=95.3%)
Disadvantages
- Dividends (0%) are below the sector average (0.51%).
- The stock's return over the last year (0%) is lower than the sector average (28.89%).
- Current debt level 35.4% has increased over 5 years from 5.67%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Frequency Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -2% | -1.6% |
| 90 days | 0% | 3% | -4.5% |
| 1 year | 0% | 28.9% | 16.5% |
FREQ vs Sector: Frequency Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -28.89% over the past year.
FREQ vs Market: Frequency Therapeutics, Inc. has significantly underperformed the market by -16.47% over the past year.
Stable price: FREQ is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: FREQ with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (14.98 $) is lower than the fair price (15.29 $).
Price not significantly lower than the fair price: The current price (14.98 $) is slightly lower than the fair price by 2.1%.
5.2. P/E
P/E vs Sector: The company's P/E (-0.26) is lower than that of the sector as a whole (26.63).
P/E vs Market: The company's P/E (-0.26) is higher than that of the market as a whole (-88.36).
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.31) is lower than that of the sector as a whole (244.09).
P/BV vs Market: The company's P/BV (1.31) is lower than that of the market as a whole (81.84).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (6.93) is lower than that of the sector as a whole (128.13).
P/S vs Market: The company's P/S indicator (6.93) is lower than that of the market as a whole (116.29).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.62) is higher than that of the sector as a whole (-21.78).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.62) is higher than that of the market as a whole (-79.49).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -0.8% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-0.8%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-28.94%).
6.4. ROE
ROE vs Sector: The company's ROE (124.7%) is higher than that of the sector as a whole (95.3%).
ROE vs Market: The company's ROE (124.7%) is higher than that of the market as a whole (23.33%).
6.6. ROA
ROA vs Sector: The company's ROA (-53.22%) is lower than that of the sector as a whole (-4.47%).
ROA vs Market: The company's ROA (-53.22%) is lower than that of the market as a whole (4.25%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-45.86%) is lower than that of the sector as a whole (-0.11%).
ROIC vs Market: The company's ROIC (-45.86%) is lower than that of the market as a whole (8.8%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.51%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
